GERN Geron Corporation

USD 3.69 -0.04 -1.072386
Icon

Geron Corporation (GERN) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 3.69

-0.04 (-1.07)%

USD 1.95B

8.23M

USD 5.17(+40.02%)

N/A

Icon

GERN

Geron Corporation (USD)
COMMON STOCK | NSD
USD 3.69
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 1.95B

N/A

USD 3.69

Geron Corporation (GERN) Stock Forecast

Show ratings and price targets of :
USD 5.17
(+40.02%)

Based on the Geron Corporation stock forecast from 5 analysts, the average analyst target price for Geron Corporation is USD 5.17 over the next 12 months. Geron Corporation’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Geron Corporation is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Geron Corporation’s stock price was USD 3.69. Geron Corporation’s stock price has changed by +1.37% over the past week, +13.19% over the past month and +48.19% over the last year.

No recent analyst target price found for Geron Corporation
No recent average analyst rating found for Geron Corporation

Company Overview Geron Corporation

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontr...Read More

https://www.geron.com

919 East Hillsdale Boulevard, Foster City, CA, United States, 94404

141

December

USD

USA

Adjusted Closing Price for Geron Corporation (GERN)

Loading...

Unadjusted Closing Price for Geron Corporation (GERN)

Loading...

Share Trading Volume for Geron Corporation Shares

Loading...

Compare Performance of Geron Corporation Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for GERN

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Geron Corporation (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO
Novo Nordisk A/S -0.04 (-0.03%) USD562.30B 46.44 4.90

ETFs Containing GERN

Symbol Name GERN's Weight Expense Ratio Price(Change) Market Cap
WBIO:LSE
WisdomTree BioRevolution .. 2.24 % 0.45 % -9.50 (-0.72%) USD6.95M

Frequently Asked Questions About Geron Corporation (GERN) Stock

Based on ratings from 5 analysts Geron Corporation's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 6 buy, sell and hold ratings.

Unfortunately we do not have enough data on GERN's stock to indicate if its a good dividend stock.

Based on targets from 5 analysts, the average taret price for GERN is USD 5.17 over the next 12 months. The maximum analyst target price is USD 6 while the minimum anlayst target price is USD 5.

Unfortunately we do not have enough data on GERN's stock to indicate if its overvalued.

The last closing price of GERN's stock was USD 3.69.

The most recent market capitalization for GERN is USD 1.95B.

Based on targets from 5 analysts, the average taret price for GERN is projected at USD 5.17 over the next 12 months. This means that GERN's stock price may go up by +40.02% over the next 12 months.

Following are ETFs with the highest allocation to Geron Corporation's stock :

WBIO:LSE

As per our most recent records Geron Corporation has 141 Employees.

Geron Corporation's registered address is 919 East Hillsdale Boulevard, Foster City, CA, United States, 94404. You can get more information about it from Geron Corporation's website at https://www.geron.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...